Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21)

被引：11

作者：

Artioli, Grazia ^{[1
]}

Giannone, Gaia ^{[2
,3
]}

Valabrega, Giorgio ^{[2
,3
]}

Maggiorotto, Furio ^{[3
]}

Genta, Sofia ^{[3
]}

Pignata, Sandro ^{[4
]}

Lorusso, Domenica ^{[5
]}

Cormio, Gennaro ^{[6
]}

Scalone, Simona ^{[7
]}

Nicoletto, Maria Ornella ^{[8
]}

Greco, Filippo ^{[9
]}

Rossi, Emanuela ^{[10
]}

Spagnoletti, Ilaria ^{[11
]}

De Giorgi, Ugo ^{[12
]}

Orditura, Michele ^{[13
]}

Mosconi, Anna Maria ^{[14
]}

Kardhashi, Anila ^{[15
]}

Bogliolo, Stefano ^{[16
,17
]}

Borgato, Lucia ^{[1
]}

机构：

[1] AULSS3 Mirano Hosp, UOC Oncol, Via Don Giacobbe Sartor 4, I-30035 Venice, Italy

[2] Univ Turin, Dept Oncol, Turin, Italy

[3] FPO IRCCS, Candiolo Canc Inst, Candiolo, TO, Italy

[4] Fdn G Pascale, Urogynecol Dept, Div Med Oncol, IRCCS Natl Canc Inst, Via Mariano Semmola 53, I-80131 Naples, Italy

[5] Fdn Policlin Univ Agostino Gemelli IRCCS, Programmaz Ric Clin, Largo Agostino Gemelli 8, I-00168 Rome, Italy

[6] Univ Bari, Dept Biomed Sci & Human Oncol DIMO, Gynecol Oncol Unit, Pzza Giulio Cesare, I-70124 Bari, Italy

[7] IRCCS, Ctr Riferimento Oncol Aviano CRO, Via Franco Gallini 2, I-33081 Aviano, PN, Italy

[8] IRCCS, Div Med Oncol 2, Veneto Inst Oncol IOV, Via Gattamelata 64, I-35128 Padua, PD, Italy

[9] Osped Legnago VR, ULSS Verona 9, UOC Oncol, Via Carlo Gianella 1, I-37045 Legnago, VR, Italy

[10] AO San Giuseppe Moscati, Med Oncol, I-83100 Avellino, Italy

[11] Osped Sacro Cuore Gesu Fatebenefratelli Benevento, UOC Oncol, Viale Principe Napoli 14-A, Benevento, Italy

[12] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Via Piero Maroncelli 40, I-47014 Meldola, FC, Italy

[13] Univ Campania Luigi Vanvitelli, UOC Oncoematol, Piazza Luigi Miraglia, I-280138 Naples, Italy

[14] Osped S Maria Misericordia, Med Oncol, Via G Dottori 1, I-06132 Perugia, Italy

[15] IRCCS Giovanni Paolo II Canc Inst, Viale Orazio Flacco 65, I-70124 Bari, Italy

[16] IRCCS Fdn Policlin, San Matteo Univ Hosp, Pavia, Italy

[17] IRCCS European Inst Oncol IEO, Milan, Italy

来源：

GYNECOLOGIC ONCOLOGY | 2021年 / 161卷 / 03期

关键词：

Ovarian cancer; BRCA 1 and BRCA 2 genes; Metachronous breast cancer; BREAST-CANCER; CARCINOMA; MUTATIONS; SURVIVAL; RISK;

D O I：

10.1016/j.ygyno.2021.04.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective. Around 15% of epithelial ovarian cancer (EOC) patients (pts) harbor a germline BRCA1 or 2 mutation, showing different features than BRCA wild-type pts. The clinical and pathological features of an Italian BRCA mutated EOC cohort were described. Methods. We retrospectively analyzed clinical, pathological and mutational data from a cohort of Italian BRCA mutated EOC pts. treated in 15 MITO centers between 1995 and 2017. Results. Three-hundred thirty-one pts. were recorded. Two-hundred forty (72%) and 91 (27.5%) pts. harbored a BRCA1 and BRCA2 mutation, respectively. Median age at diagnosis was 52 years. The most frequent diagnosis was a high grade serous FIGO III or IV EOC and platinum doublet in first-line was administered to almost all pts. Fifty-three % of them had no residual disease (R = 0) at surgery. Median progression-free-survival (mPFS) afterfirst-line chemotherapy was 29 months. Expected percentage of pts. alive at 5 years was 72.5% (CI 60.2-80.8%) and R = 0 predicted a significantly longer overall survival (OS). Sixty-six pts. (19,9%) had both an EOC and a breast cancer (BC) diagnosis. The first diagnosis was BC in 81,8% of cases with a mean interval between the two diagnoses (IBTDs) of 132.4 months. Mutational data show that the founder mutation c.5266dupC in BRCA1 was the most frequently recorded. Conclusions. This is the largest Italian BRCA mutEOC cohort. The only predictor of longer OS was R = 0. EOC pts. that developed subsequently a BC are long-term survivors. (c) 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).

引用

页码：755 / 761

页数：7

共 40 条

[11] Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy [J].

Cini, Giulia ;

Mezzavilla, Massimo ;

Della Puppa, Lara ;

Cupelli, Elisa ;

Fornasin, Alessio ;

D'Elia, Angela Valentina ;

Dolcetti, Riccardo ;

Damante, Giuseppe ;

Bertok, Sara ;

Miolo, Gianmaria ;

Maestro, Roberta ;

de Paoli, Paolo ;

Amoroso, Antonio ;

Viel, Alessandra .

BMC MEDICAL GENETICS, 2016, 17

[12] Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer [J].

Domchek, Susan M. ;

Jhaveri, Komal ;

Patil, Sujata ;

Stopfer, Jill E. ;

Hudis, Clifford ;

Powers, Jacquelyn ;

Stadler, Zsofia ;

Goldstein, Laura ;

Kauff, Noah ;

Khasraw, Mustafa ;

Offit, Kenneth ;

Nathanson, Katherine L. ;

Robson, Mark .

CANCER, 2013, 119 (07) :1344-1348

[13] Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) [J].

du Bois, Andreas ;

Reuss, Alexander ;

Pujade-Lauraine, Eric ;

Harter, Philipp ;

Ray-Coquard, Isabelle ;

Pfisterer, Jacobus .

CANCER, 2009, 115 (06) :1234-1244

[14] Founder mutations in BRCA1 and BRCA2 genes [J].

Ferla, R. ;

Calo, V. ;

Cascio, S. ;

Rinaldi, G. ;

Badalamenti, G. ;

Carreca, I. ;

Surmacz, E. ;

Coliucci, G. ;

Bazan, V. ;

Russo, A. .

ANNALS OF ONCOLOGY, 2007, 18 :93-98

[15] Patients with double primary tumors in the breast and ovary - Clinical characteristics and BRCA1-2 mutations status [J].

Fishman, A ;

Dekel, E ;

Chetrit, A ;

Lerner-Geva, L ;

Bar-Am, A ;

Beck, D ;

Beller, U ;

Ben-Baruch, G ;

Piura, B ;

Friedman, E ;

Struewing, JP ;

Modan, B .

GYNECOLOGIC ONCOLOGY, 2000, 79 (01) :74-78

[16]

Gruppo di Lavoro AIOM-SIGU-SIBIOC-SIAPEC-IAP, 2015, RACC IMPL TEST PROT

[17]

Howlader N., 2019, SEER Cancer Statistics Review, 1975-2016

[18] Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers [J].

Kuchenbaecker, Karoline B. ;

Hopper, John L. ;

Barnes, Daniel R. ;

Phillips, Kelly-Anne ;

Mooij, Thea M. ;

Roos-Blom, Marie-Jose ;

Jervis, Sarah ;

van Leeuwen, Flora E. ;

Milne, Roger L. ;

Andrieu, Nadine ;

Goldgar, David E. ;

Terry, Mary Beth ;

Rookus, Matti A. ;

Easton, Douglas F. ;

Antoniou, Antonis C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23) :2402-2416

[19] ClinVar at five years: Delivering on the promise [J].

Landrum, Melissa J. ;

Kattman, Brandi L. .

HUMAN MUTATION, 2018, 39 (11) :1623-1630

[20]

Loizzi Vera, 2018, Oncotarget, V9, P22353, DOI 10.18632/oncotarget.24959

← 1 2 3 4 →